Missouri

Missouri is more active than many no-pathway states because legislators have repeatedly considered veteran- and research-oriented psilocybin bills. HB 829 in 2025 would have linked legal protections and study infrastructure to alternative therapies, but its calendar death means the policy effect is signalling rather than implementation.###

The state's practical access context is therefore split. St. Louis has serious academic psychedelic research and ordinary ketamine/esketamine care, while statewide law has not caught up with that research environment. Reimbursement is most legible for Spravato through MO HealthNet prior authorisation; off-label IV/IM ketamine remains a separate coverage and self-pay question.###

Missouri's research centre of gravity is Washington University in St. Louis. ClinicalTrials.gov lists a Washington University psilocybin study on precision functional brain mapping, and the university's CHIRP unit describes a clinical-trials framework for psychedelic-assisted therapy. Washington University materials also describe COMPASS Pathfinder psilocybin studies for treatment-resistant depression.###

Ketamine research and care are also substantial. Washington University's Treatment-Resistant Depression Program offers esketamine, and its Healthy Mind Lab has published and described ketamine work in late-life treatment-resistant depression. Missouri is therefore a high-research, low-access state rather than a low-activity state.###

Missouri has no psilocybin facilitator licensing, service-centre rules, state product supply chain or therapeutic access registry. If a future bill passes, the likely implementation questions will include Department of Health and Senior Services or Department of Mental Health ownership, trial partnerships, veteran eligibility, liability protections, product testing and state funding.###

Current implementation is handled by federal research controls, university IRBs, controlled-substance registrations, hospital policies and payer prior authorisation. For readers, the key operational point is that Missouri already has credible research infrastructure, but it has not translated into non-research patient access.###

St. Louis is the obvious regional spotlight. Washington University combines CHIRP, the Healthy Mind Lab, a treatment-resistant-depression programme, psilocybin imaging studies and esketamine care. That makes the city one of the stronger Midwest research nodes even without a state-regulated access pathway.###

The policy ecosystem includes recurring legislative interest around veterans and alternative therapies. The gap is implementation: there is no state board, clinic approval process, facilitator training pathway or public access programme.###

Missouri's next 12 to 24 months are likely to be shaped by research outputs and renewed legislation. The state has enough academic infrastructure to support serious trials, and the political interest around veterans may return in future sessions.###

Actual patient access will not change unless a bill passes or a federally approved product becomes available. Even then, reimbursement, provider training and institutional willingness would determine how much access moves beyond St. Louis research centres.###